Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: Effect of incorporating higher-affinity ligands and potential new applications

被引:18
作者
Locuson, CW
Wahlstrom, JL
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Pfizer Inc, Pharmacokinet Dynam & Metab, Pfizer Global Res & Dev, St Louis Labs, St Louis, MO USA
关键词
D O I
10.1124/dmd.105.004325
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, two new classes of reversible inhibitors, the benzbromarones (BZBRs) and the N-3 substituted phenobarbitals (PBs), were used to study the active site characteristics of CYP2C9 and 2C19, respectively. Since these ligands are some of the first CYP2C ligands to extend into the low nanomolar K-i range (K-i < 100 nM), they were subjected to three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Given that BZBRs or the PB ligands bind very tightly, it can be assumed that these structures complement the binding pocket(s) for these enzymes. Thus, the resulting models should output a 3D arrangement of interaction sites predicted to be important for near optimal binding to the CYP2C9 and CYP2C19 enzymes. These predicted interaction regions may then improve the ability to predict drug-drug interactions. The resulting models generated from these new high affinity ligands are discussed, as are novel uses of 3D-QSAR and molecular modeling techniques that may be useful in the study of cytochromes P450 specifically.
引用
收藏
页码:873 / 878
页数:6
相关论文
共 21 条
[1]   Kohonen maps for prediction of binding to human cytochrome P450 3A4 [J].
Balakin, KV ;
Ekins, S ;
Bugrim, A ;
Ivanenkov, YA ;
Korolev, D ;
Nikolsky, YV ;
Skorenko, AV ;
Ivashchenko, AA ;
Savchuk, NP ;
Nikolskaya, T .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) :1183-1189
[2]   Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9 [J].
Dickmann, LJ ;
Locuson, CW ;
Jones, JP ;
Rettie, AE .
MOLECULAR PHARMACOLOGY, 2004, 65 (04) :842-850
[3]   Generation and evaluation of a CYP2C9 heteroactivation pharmacophore [J].
Egnell, AC ;
Eriksson, C ;
Albertson, N ;
Houston, B ;
Boyer, S .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03) :878-887
[4]  
Ekins S, 2001, DRUG METAB DISPOS, V29, P936
[5]   Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials [J].
Evers, A ;
Gohlke, H ;
Klebe, G .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 334 (02) :327-345
[6]   Validation of model of cytochrome p450 2D6:: An in silico tool for predicting metabolism and inhibition [J].
Kemp, CA ;
Flanagan, JU ;
van Eldik, AJ ;
Maréchal, JD ;
Wolf, CR ;
Roberts, GCK ;
Paine, MJI ;
Sutcliffe, MJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (22) :5340-5346
[7]   Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors [J].
Locuson, CW ;
Suzuki, H ;
Rettie, AE ;
Jones, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6768-6776
[8]   Quantitative binding models for CYP2C9 based on benzbromarone analogues [J].
Locuson, CW ;
Rock, DA ;
Jones, JP .
BIOCHEMISTRY, 2004, 43 (22) :6948-6958
[9]   A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives [J].
Locuson, CW ;
Wahlstrom, JL ;
Rock, DA ;
Rock, DA ;
Jones, JP .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :967-971
[10]  
Martín-Biosca Y, 2000, QUANT STRUCT-ACT REL, V19, P247, DOI 10.1002/1521-3838(200006)19:3<247::AID-QSAR247>3.0.CO